EFSA speaks on disputed lutein claims: Only “normal vision” eligible
date:Jun 16, 2012

While DSM is referenced, the claim was a general function, article 13 claim that was rejected in 2009 and 2011. Theinsufficientconclusion prompted an NDA reassessment with additional data added to the dossier by DSM, its partner Kemin, but the NDA remained unimpressed.

Aside from being criticised for its methodology in rejecting peer-reviewed and validated intervention studies, it is its decision not to assess the claims submitted - claims that exactly mimic those approved by French authoritie
2/8 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
05/23 18:38